Portal de Periódicos da CAPES

Imaging biomarkers in prostate cancer: role of PET/CT and MRI

2015; Springer Science+Business Media; Volume: 42; Issue: 4 Linguagem: Inglês

10.1007/s00259-014-2982-5

1619-7089

Maria Picchio, Paola Mapelli, Valeria Panebianco, Paolo Castellucci, Elena Incerti, Alberto Briganti, Giorgio Gandaglia, Margarita Kirienko, Flavio Barchetti, Cristina Nanni, Francesco Montorsi, Luigi Gianolli, Stefano Fanti,

Radiomics and Machine Learning in Medical Imaging

Prostate-specific antigen (PSA) is currently the most widely used biomarker of prostate cancer (PCa). PSA suggests the presence of primary tumour and disease relapse after treatment, but it is not able to provide a clear distinction between locoregional and distant disease. Molecular and functional imaging, that are able to provide a detailed and comprehensive overview of PCa extension, are more reliable tools for primary tumour detection and disease extension assessment both in staging and restaging. In the present review we evaluate the role of PET/CT and MRI in the diagnosis, staging and restaging of PCa, and the use of these imaging modalities in prognosis, treatment planning and response assessment. Innovative imaging strategies including new radiotracers and hybrid scanners such as PET/MRI are also discussed.